Company / R&D per Share
Corcept Therapeutics Incorporated R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.43
FY2025
5-year range
$0.76 / $2.43
FY2021-FY2025
Trend
+1.6%
vs FY2024
Sector context
#88 of 208
Health Care
What the data says
At $2.43, Corcept Therapeutics Incorporated's r&d per share ranks #88 of 208 in the Health Care sector. R&D per Share has increased for 7 consecutive years, from $0.21 in FY2018 to $2.43 in FY2025.
Based on SEC 10-K filings.
2.43 in FY2025 with a 5-year CAGR of +29.9%.
Improved from $1.71 to $2.43 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +30.8%
- 5-Year CAGR
- +29.9%
- 10-Year CAGR
- -
Sector benchmark
#88 of 208 in Health CareTop 42% of 208This company $2.43 Sector average $12.19
▼
-80.1% below sector average
Key checks
Key Insights
- Corcept Therapeutics Incorporated's r&d per share has grown for 7 consecutive years.
- In FY2025, r&d per share increased 1.6% year-over-year.
- Ranks #88 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.43 | +1.6% |
| FY2024 | $2.39 | +39.7% |
| FY2023 | $1.71 | +57.8% |
| FY2022 | $1.08 | +42.1% |
| FY2021 | $0.76 | +16.1% |
| FY2020 | $0.66 | +87.1% |
| FY2019 | $0.35 | +68.9% |
| FY2018 | $0.21 | -42.0% |
| FY2017 | $0.36 | +113.8% |
| FY2016 | $0.17 | +10.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026